Symbols / MIST $1.78 +6.59%
MIST Chart
About
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 151.60M |
| Enterprise Value | 155.44M | Income | -58.01M | Sales | — |
| Book/sh | 0.20 | Cash/sh | 0.81 | Dividend Yield | — |
| Payout | 0.00% | Employees | 33 | IPO | — |
| P/E | — | Forward P/E | -2.98 | PEG | — |
| P/S | — | P/B | 8.81 | P/C | — |
| EV/EBITDA | -2.72 | EV/Sales | — | Quick Ratio | 7.99 |
| Current Ratio | 8.23 | Debt/Eq | 279.05 | LT Debt/Eq | — |
| EPS (ttm) | -0.79 | EPS next Y | -0.60 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-12 | ROA | -41.97% |
| ROE | -260.65% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 85.17M |
| Shs Float | 84.01M | Short Float | 8.78% | Short Ratio | 3.27 |
| Short Interest | — | 52W High | 3.06 | 52W Low | 0.62 |
| Beta | 0.54 | Avg Volume | 4.63M | Volume | 1.60M |
| Target Price | $6.60 | Recom | Buy | Prev Close | $1.67 |
| Price | $1.78 | Change | 6.59% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.60
Mean price target
2. Current target
$1.78
Latest analyst target
3. DCF / Fair value
$-5.47
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.78
Low
$2.00
High
$8.00
Mean
$6.60
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-06 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-12-16 | main | Wells Fargo | Overweight → Overweight | $8 |
| 2025-12-15 | up | TD Cowen | Hold → Buy | $8 |
| 2025-12-15 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-09-11 | init | Wells Fargo | — → Overweight | $4 |
| 2025-04-01 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-28 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-03-17 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-02-28 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-01-27 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-10-14 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-08-22 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-08-22 | init | Rodman & Renshaw | — → Buy | $9 |
| 2024-07-01 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-05-30 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-03-22 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-03-05 | main | Piper Sandler | Overweight → Overweight | $5 |
| 2024-02-26 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2023-12-27 | main | TD Cowen | Outperform → Outperform | $9 |
- Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST) - Seeking Alpha hu, 15 Jan 2026 08
- Milestone Pharmaceuticals (MIST): Taking Stock of Valuation After FDA Approval of CARDAMYST Nasal Spray - Yahoo Finance ue, 16 Dec 2025 08
- Milestone Pharma (Nasdaq: MIST) has Dec 13 PDUFA target for CARDAMYST in PSVT; launch plans set - Stock Titan Wed, 12 Nov 2025 08
- Milestone Pharmaceuticals (MIST) Price Target Increased by 76.00% to 6.73 - Nasdaq Sun, 21 Dec 2025 08
- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Rating of "Hold" from Brokerages - MarketBeat hu, 05 Mar 2026 08
- MIST Stock Upgraded to 'Buy' by TD Cowen with New Price Target | - GuruFocus Mon, 15 Dec 2025 08
- Milestone Pharmaceuticals (MIST) Is Down 16.3% After First-in-Decades At-Home PSVT Drug Approval - Has The Bull Case Changed? - simplywall.st Wed, 17 Dec 2025 08
- Insider Sale: President and CEO of $MIST Sells 43,000 Shares - Quiver Quantitative Fri, 09 Jan 2026 08
- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Could Be 44% Below Their Intrinsic Value Estimate - Yahoo Finance ue, 18 Nov 2025 08
- Milestone (NASDAQ: MIST) gains FDA approval for self-use CARDAMYST PSVT spray - Stock Titan Fri, 12 Dec 2025 08
- Milestone Pharmaceuticals (MIST) Projected to Post Earnings on Thursday - MarketBeat hu, 05 Mar 2026 06
- Wells Fargo Raises Price Target for Milestone Pharmaceuticals (M - GuruFocus ue, 16 Dec 2025 08
- Milestone Pharmaceuticals: Playing The Long Ball In Cardiovascular Treatment (NASDAQ:MIST) - Seeking Alpha ue, 07 Oct 2025 07
- Milestone Pharma (Nasdaq: MIST) grants 65,000 options per Nasdaq Listing Rule 5635(c)(4) - Stock Titan ue, 04 Nov 2025 08
- Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects - Yahoo Finance ue, 25 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 167577 | 375315.0 | — | Sale at price 1.93 - 2.32 per share. | OLIVETO JOSEPH GERARD | Chief Executive Officer | — | 2026-01-26 00:00:00 | D |
| 1 | 64746 | 145851.0 | — | Sale at price 1.93 - 2.32 per share. | MULLER LORENZ ANDREW | Officer | — | 2026-01-26 00:00:00 | D |
| 2 | 70252 | 158209.0 | — | Sale at price 1.93 - 2.32 per share. | HASIJA AMIT | Chief Financial Officer | — | 2026-01-26 00:00:00 | D |
| 3 | 70252 | 158209.0 | — | Sale at price 1.93 - 2.32 per share. | BHARUCHA DAVID | Officer | — | 2026-01-26 00:00:00 | D |
| 4 | 70252 | 158209.0 | — | Sale at price 1.93 - 2.32 per share. | NELSON JEFFREY EDWARD | Chief Operating Officer | — | 2026-01-26 00:00:00 | D |
| 5 | 66600 | nan | — | — | OLIVETO JOSEPH GERARD | Chief Executive Officer | — | 2026-01-26 00:00:00 | D |
| 6 | 20100 | nan | — | — | MULLER LORENZ ANDREW | Officer | — | 2026-01-26 00:00:00 | D |
| 7 | 20100 | nan | — | — | HASIJA AMIT | Chief Financial Officer | — | 2026-01-26 00:00:00 | D |
| 8 | 20100 | nan | — | — | BHARUCHA DAVID | Officer | — | 2026-01-26 00:00:00 | D |
| 9 | 20100 | nan | — | — | NELSON JEFFREY EDWARD | Chief Operating Officer | — | 2026-01-26 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -37.83M | -57.04M | -58.30M | -42.98M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -41.52M | -59.69M | -58.39M | -42.85M |
| ReconciledDepreciation | 105.00K | 92.00K | 89.00K | 93.00K |
| EBITDA | -37.83M | -57.04M | -58.30M | -42.98M |
| EBIT | -37.94M | -57.13M | -58.39M | -43.07M |
| NetInterestIncome | 583.00K | 1.41M | 1.25M | 220.00K |
| InterestExpense | 3.58M | 2.55M | 0.00 | |
| InterestIncome | 4.16M | 3.97M | 1.25M | 220.00K |
| NormalizedIncome | -41.52M | -59.69M | -58.39M | -42.85M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -41.52M | -59.69M | -58.39M | -42.85M |
| TotalExpenses | 42.10M | 62.10M | 64.64M | 58.07M |
| TotalOperatingIncomeAsReported | -42.10M | -61.10M | -59.64M | -43.07M |
| DilutedAverageShares | 62.21M | 42.96M | 42.45M | 41.83M |
| BasicAverageShares | 62.21M | 42.96M | 42.45M | 41.83M |
| DilutedEPS | -0.67 | -1.39 | -1.38 | -1.02 |
| BasicEPS | -0.67 | -1.39 | -1.38 | -1.02 |
| DilutedNIAvailtoComStockholders | -41.52M | -59.69M | -58.39M | -42.85M |
| NetIncomeCommonStockholders | -41.52M | -59.69M | -58.39M | -42.85M |
| NetIncome | -41.52M | -59.69M | -58.39M | -42.85M |
| NetIncomeIncludingNoncontrollingInterests | -41.52M | -59.69M | -58.39M | -42.85M |
| NetIncomeContinuousOperations | -41.52M | -59.69M | -58.39M | -42.85M |
| TaxProvision | 0.00 | |||
| PretaxIncome | -41.52M | -59.69M | -58.39M | -42.85M |
| NetNonOperatingInterestIncomeExpense | 583.00K | 1.41M | 1.25M | 220.00K |
| InterestExpenseNonOperating | 3.58M | 2.55M | 0.00 | |
| InterestIncomeNonOperating | 4.16M | 3.97M | 1.25M | 220.00K |
| OperatingIncome | -42.10M | -61.10M | -59.64M | -43.07M |
| OperatingExpense | 42.10M | 62.10M | 64.64M | 58.07M |
| ResearchAndDevelopment | 14.36M | 31.05M | 39.83M | 38.67M |
| SellingGeneralAndAdministration | 27.75M | 31.05M | 24.81M | 19.40M |
| SellingAndMarketingExpense | 11.00M | 15.11M | 9.10M | 7.00M |
| GeneralAndAdministrativeExpense | 16.74M | 15.93M | 15.72M | 12.40M |
| OtherGandA | 16.74M | 15.93M | 15.72M | 12.40M |
| TotalRevenue | 0.00 | 1.00M | 5.00M | 15.00M |
| OperatingRevenue | 0.00 | 1.00M | 5.00M | 15.00M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 53.35M | 33.48M | 34.29M | 29.90M |
| ShareIssued | 53.35M | 33.48M | 34.29M | 29.90M |
| NetDebt | 28.04M | 36.01M | ||
| TotalDebt | 54.80M | 51.77M | 2.49M | 698.00K |
| TangibleBookValue | 13.15M | 16.77M | 66.35M | 112.60M |
| InvestedCapital | 66.50M | 66.54M | 66.35M | 112.60M |
| WorkingCapital | 65.80M | 65.81M | 65.66M | 112.15M |
| NetTangibleAssets | 13.15M | 16.77M | 66.35M | 112.60M |
| CapitalLeaseObligations | 1.45M | 2.00M | 2.49M | 698.00K |
| CommonStockEquity | 13.15M | 16.77M | 66.35M | 112.60M |
| TotalCapitalization | 66.50M | 66.54M | 66.35M | 112.60M |
| TotalEquityGrossMinorityInterest | 13.15M | 16.77M | 66.35M | 112.60M |
| StockholdersEquity | 13.15M | 16.77M | 66.35M | 112.60M |
| OtherEquityInterest | 53.08M | 48.46M | 34.35M | 52.94M |
| GainsLossesNotAffectingRetainedEarnings | -1.63M | |||
| ForeignCurrencyTranslationAdjustments | -1.63M | |||
| RetainedEarnings | -367.55M | -326.03M | -266.34M | -207.95M |
| AdditionalPaidInCapital | 39.57M | 33.83M | 24.44M | 15.71M |
| CapitalStock | 288.05M | 260.50M | 273.90M | 251.90M |
| CommonStock | 288.05M | 260.50M | 273.90M | 251.90M |
| TotalLiabilitiesNetMinorityInterest | 62.35M | 58.45M | 8.13M | 7.25M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 54.23M | 51.23M | 2.00M | 474.00K |
| LongTermDebtAndCapitalLeaseObligation | 54.23M | 51.23M | 2.00M | 474.00K |
| LongTermCapitalLeaseObligation | 874.00K | 1.46M | 2.00M | 474.00K |
| LongTermDebt | 53.35M | 49.77M | ||
| CurrentLiabilities | 8.13M | 7.23M | 6.14M | 6.78M |
| CurrentDebtAndCapitalLeaseObligation | 571.00K | 546.00K | 495.00K | 224.00K |
| CurrentCapitalLeaseObligation | 571.00K | 546.00K | 495.00K | 224.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.50M | 712.00K | 2.57M | 1.46M |
| PayablesAndAccruedExpenses | 5.05M | 5.97M | 3.07M | 5.09M |
| CurrentAccruedExpenses | 3.12M | 1.99M | 808.00K | 709.00K |
| Payables | 1.93M | 3.98M | 2.26M | 4.38M |
| OtherPayable | 1.46M | |||
| AccountsPayable | 1.93M | 3.98M | 2.26M | 4.38M |
| TotalAssets | 75.50M | 75.23M | 74.48M | 119.85M |
| TotalNonCurrentAssets | 1.57M | 2.19M | 2.68M | 926.00K |
| NetPPE | 1.57M | 2.19M | 2.68M | 926.00K |
| AccumulatedDepreciation | -291.00K | -191.00K | -120.00K | -239.00K |
| GrossPPE | 1.86M | 2.38M | 2.80M | 1.17M |
| Leases | 85.00K | 85.00K | 102.00K | 26.00K |
| OtherProperties | 1.38M | 1.92M | 2.42M | 711.00K |
| MachineryFurnitureEquipment | 403.00K | 383.00K | 275.00K | 428.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 73.93M | 73.03M | 71.80M | 118.92M |
| PrepaidAssets | 1.84M | 3.18M | 6.00M | 4.30M |
| Receivables | 2.39M | 3.85M | 1.21M | 483.00K |
| OtherReceivables | 676.00K | 2.42M | 6.00K | 127.00K |
| TaxesReceivable | 1.11M | 907.00K | 592.00K | 356.00K |
| AccruedInterestReceivable | 604.00K | 528.00K | 615.00K | |
| CashCashEquivalentsAndShortTermInvestments | 69.69M | 66.00M | 64.58M | 114.14M |
| OtherShortTermInvestments | 44.38M | 52.24M | 56.95M | 0.00 |
| CashAndCashEquivalents | 25.31M | 13.76M | 7.64M | 114.14M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -28.88M | -46.54M | -52.74M | -33.22M |
| IssuanceOfDebt | 0.00 | 50.00M | 0.00 | |
| IssuanceOfCapitalStock | 27.26M | 0.00 | 2.63M | 0.00 |
| CapitalExpenditure | -33.00K | -112.00K | -272.00K | |
| EndCashPosition | 25.31M | 13.76M | 7.64M | 114.14M |
| BeginningCashPosition | 13.76M | 7.64M | 114.14M | 72.31M |
| ChangesInCash | 11.55M | 6.12M | -106.50M | 41.83M |
| FinancingCashFlow | 32.12M | 47.79M | 3.09M | 5.05M |
| CashFlowFromContinuingFinancingActivities | 32.12M | 47.79M | 3.09M | 5.05M |
| NetOtherFinancingCharges | -2.78M | |||
| ProceedsFromStockOptionExercised | 4.86M | 574.00K | 458.00K | 5.05M |
| NetCommonStockIssuance | 27.26M | 0.00 | 2.63M | 0.00 |
| CommonStockIssuance | 27.26M | 0.00 | 2.63M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | 50.00M | 0.00 | |
| NetLongTermDebtIssuance | 0.00 | 50.00M | 0.00 | |
| LongTermDebtIssuance | 0.00 | 50.00M | 0.00 | |
| InvestingCashFlow | 8.28M | 4.76M | -57.12M | 70.00M |
| CashFlowFromContinuingInvestingActivities | 8.28M | 4.76M | -57.12M | 70.00M |
| NetInvestmentPurchaseAndSale | 8.32M | 4.87M | -56.85M | 70.00M |
| SaleOfInvestment | 121.87M | 142.00M | 29.00M | 85.00M |
| PurchaseOfInvestment | -113.55M | -137.13M | -85.85M | -15.00M |
| NetPPEPurchaseAndSale | -33.00K | -112.00K | -272.00K | 0.00 |
| PurchaseOfPPE | -33.00K | -112.00K | -272.00K | 0.00 |
| OperatingCashFlow | -28.85M | -46.42M | -52.47M | -33.22M |
| CashFlowFromContinuingOperatingActivities | -28.85M | -46.42M | -52.47M | -33.22M |
| ChangeInWorkingCapital | 3.66M | 1.24M | -3.26M | 2.26M |
| ChangeInOtherWorkingCapital | -17.00K | 18.00K | 81.00K | 26.00K |
| ChangeInPayablesAndAccruedExpense | 875.00K | 1.04M | -907.00K | 637.00K |
| ChangeInPrepaidAssets | 1.34M | 2.83M | -1.71M | 1.13M |
| ChangeInReceivables | 1.46M | -2.64M | -730.00K | 465.00K |
| OtherNonCashItems | 3.58M | 2.55M | ||
| StockBasedCompensation | 5.78M | 9.53M | 9.05M | 7.28M |
| AmortizationOfSecurities | -454.00K | -162.00K | -97.00K | 0.00 |
| DepreciationAmortizationDepletion | 105.00K | 92.00K | 89.00K | 93.00K |
| DepreciationAndAmortization | 105.00K | 92.00K | 89.00K | 93.00K |
| Depreciation | 105.00K | 92.00K | 89.00K | 93.00K |
| OperatingGainsLosses | 8.00K | 141.00K | ||
| GainLossOnSaleOfPPE | 8.00K | 0.00 | 141.00K | 0.00 |
| NetIncomeFromContinuingOperations | -41.52M | -59.69M | -58.39M | -42.85M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for MIST
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|